Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 10;567(2):132-7.
doi: 10.1016/j.gene.2015.04.087. Epub 2015 May 14.

IFNA2: The prototypic human alpha interferon

Affiliations
Review

IFNA2: The prototypic human alpha interferon

Franciane Paul et al. Gene. .

Abstract

The human interferon α2 (IFNα2) was the first highly active IFN subtype to be cloned in the early eighties. It was also the first IFN and the first cytokine to be produced and commercialized by the pharmaceutical industry. Ipso facto it became the favorite IFNα subtype for academic researchers. For this fortunate reason IFNα2 has been at the origin of most discoveries related to the mechanism of action of type I interferons.

Keywords: Cytokine; Interferon α2; Type I interferon.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Induction of type I-IFNs
Damage and pathogen associated molecular patterns are recognized by cytosolic sensors and/or endosomal receptors which activate several pathways leading to the activation of IRF kinases and the subsequent phosporylation of IRF3 and IRF7.Once phosphorylated, these IRF translocate into the nucleus, bind to the promoter of type I IFN genes and activate their transcription. Unlike IFNB gene, IFNA2 gene requires both IRF3 and IRF7 activation to be induced. cGAS: Cyclic GMP-AMP synthase; CpG DNA: DNA with cytidine-phosphate-guanosine motifs; DAI: DNA-dependent activator of IFNregulatory factors; dsRNA: double strand RNA; IKK: inhibitor of kappaB kinase; IRAK: Interleukin-1 receptor-associated kinase; IRF: Interferon regulatory factors; MDA5: Melanoma Differentiation-Associated protein 5; MyD88: myeloid differentiation primary response protein 88; RIG-I: retinoic acid-inducible gene 1; STING: Stimulator of interferon genes; TBK: TANK-binding kinase; TLR: Toll-like receptor; TRIF: Toll/IL-1 receptor (TIR) domain-containing adaptor inducing IFNβ, TRAF: TNF receptor associated factors; VRE: virus responsive element.
Figure 2
Figure 2. Canonical JAK/STAT signalling pathway of type I-IFNs
Type I-IFN/IFNAR2/IFNAR1 ternary complex induces transphosphorylation of receptor associated JAK kinases which in turn phosphorylate specific tyrosine residues on IFNAR1 and IFNAR2. These phosphorylated tyrosine residues are docking sites for signal transducers and activators of transcription (STAT) which are then recruited to the receptor complex and phosporylated (pSTAT) on specific tyrosine residue. pSTAT2 and pSTAT1 heterodimerize to form together with IRF9 the ISGF3 complex which translocates into the nucleus and binds to IFN stimulated responsive elements (ISRE) in the regulatory region of IFN-stimulated genes (ISG)

References

    1. Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine Growth Factor Rev. 2015 In Press. - PMC - PubMed
    1. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Moller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224–31. - PubMed
    1. Bis RL, Stauffer TM, Singh SM, Lavoie TB, Mallela KM. High yield soluble bacterial expression and streamlined purification of recombinant human interferon alpha-2a. Protein Expr Purif. 2014;99:138–46. - PMC - PubMed
    1. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, Salem S, Radovanovic I, Grant AV, Adimi P, Mansouri N, Okada S, Bryant VL, Kong XF, Kreins A, Velez MM, Boisson B, Khalilzadeh S, Ozcelik U, Darazam IA, Schoggins JW, Rice CM, Al-Muhsen S, Behr M, Vogt G, Puel A, Bustamante J, Gros P, Huibregtse JM, Abel L, Boisson-Dupuis S, Casanova JL. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012;337:1684–8. - PMC - PubMed
    1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975–90. - PMC - PubMed

Publication types